You are here
Circulating Diagnostic Markers of Infectious Disease
Phone: (781) 244-4505
Email: mjohn@pathovacs.com
Phone: (781) 244-4505
Email: mjohn@pathovacs.com
Contact: Manohar John
Address:
Phone: (781) 244-4505
Type: Nonprofit College or University
The focus of this STTR phase I component is on proof-of-concept studies demonstrating applicability of technical approaches for identificationof circulatory diagnostic markers for infectious disease. Therefore, the primary objective of this project is to determine feasibility of one suchtechnical approach called Proteomics-based Expression Library Screening (PELS), for identification of pathogen-derived proteins shed incirculation (shed proteins) during the process of infection. PELS is a proprietary, fully validated, highly sensitive platform proteome miningtool for discovery of the gamut of protein antigens expressed by any microbe during infection. Specifically, proof-of-concept will bedemonstrated by identifying a panel of proteins unique to virulent Brucella melitensis strain16 M that are shed in murine sera, collected atvarious time points following experiment infection of mice with the cognate pathogen. Phase II studies will involve application of this Phase Ivalidatedplatform technical approach to defining shed proteins in sera of patients infected with Brucella species and Rickettsia prowazekii,and in sera and cerebrospinal fluid of individuals infected with the Venezuelan Equine Encephalitis virus, followed by marker validation anddevelopment of prototype diagnostic assays. Phase III will involve partnered in vitro diagnostic instrument development and validationstudies for FDA approval, and commercialization.
* Information listed above is at the time of submission. *